is a speaker and consultant of Theratechnologies. 75. One reason for that is that this tier does not include penny stocks. Gary Littlejohn. . 6. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. is a pharmaceutical company. com. Marsolais’ presentation will be available through. - 2023 Q3 positive adjusted EBITDA to be achieved. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. 521. Montréal, Québec, Canada . (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. Theratechnologies Appoints New Board Member. Further. Phone Number 15143319691. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 38. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. Website. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Wainwright NASH Investor Conference. Paul Levesque - President. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. com uses cookies on this site. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. Stockhouse. “This is yet another major achievement for our oncology program. com uses cookies on this site. We currently market prescription products for people with. The abstracts are now available at aacr. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company develops treatments for lipodystrophy . T. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. European Headquarters. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. 8 and 1. com uses cookies on this site. Find the latest Theratechnologies Inc. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. 46. 57%) Q1 2020 Earnings Call. Theratechnologies Inc. 2. Cookies are used to offer you a better browsing experience and to analyze our traffic. Focused on small-cap companies and sectors. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. com uses cookies on this site. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. ( THTX 3. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. MONTREAL, Dec. . Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. [email protected] Inc: Overview. Theratechnologies Inc. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. We also use them to share usage information with our partners. MONTREAL, Nov. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. We also use them to share usage. 617-356-1009. Theratechnologies Appoints New Board Member. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. View real-time stock prices and stock quotes for a full financial overview. Company Type For Profit. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. By continuing to use our service, you agree to our use of cookies. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. . 25 to $1. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. 71. 35 as of 10:41 a. 5000 0. View real-time stock prices and stock quotes for a full financial overview. Track Theratechnologies Inc. Theratechnologies Inc. -986. 31K. We also use them to share usage. T. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. 40 f102M H1. (THTX) stock. 71%. Theratechnologies Inc. MONTREAL, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 51 to 200 Employees. com uses cookies on this site. This module allows you to check different measures of market premium (i. 4. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. 40%. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. MONTREAL, Jan. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. Stockhouse. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - 2023 Q3 positive adjusted EBITDA to be. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. We also use them to share usage. FDA for its IV push form of administration of Trogarzo. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. 5% workforce reduction. We also use them to share usage. FAQ – Émetteurs inscrits NOUVEAU. (THTX) Stock Price, Quote & News - Stock Analysis -20. TH | May 19, 2023. TH | May 19, 2023. By continuing to use our service, you agree to our use of cookies. MONTREAL, Oct. Senior Director, Investor Relations. $44. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Image source: The Motley Fool. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com. We also use them to share usage. Phone Number (514) 336-7800. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 00 to $36. TH Stock Message Board for Investors. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. On average, they expect the company's stock price to reach $36. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Stockhouse. Stockhouse. (TH. 81 million for the quarter. com uses cookies on this site. ET. com. The Company currently commercializes two products in the field of HIV. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. R. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. - Q3 2022 North American Revenue Growth of 19%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies's earnings have been declining at an average annual rate of -35. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. About Us | Theratechnologies Inc. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. GUD | Complete Knight Therapeutics Inc. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. com uses cookies on this site. . MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . licensed the product from TaiMed Biologics, Inc. MONTREAL, Oct. Montréal, Québec, Canada . By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. Theratechnologies inc. The business had revenue of $27. 17. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. 65 per cent to C$1. (TH. 05M. Market Cap. m. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Trogarzo® and. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. Vice President, Communications and Corporate Affairs. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. During the last trading day the stock fluctuated 12. Theratechnologies to Announce Financial Results for Its First Quarter 2022. The company was. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. NEW YORK, Dec. Montreal-based biopharmaceutical company Theratechnologies Inc. MONTREAL, Sept. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. Theratechnologies Announces 1-for-4 Reverse Stock Split. . : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. Find the latest Theratechnologies Inc. THTX | Complete Theratechnologies Inc. 33 +0. 26 +15. MONTREAL, Feb. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. MONTREAL, Nov. OTCQX – this is the premium tier of OTC stocks. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 54% and a negative trailing twelve-month return on equity of 1,116. FY2023 revenue guidance range set between $90 million and $95 million. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. For investor inquiries: Leah Gibson. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. MONTREAL, Aug. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Investor Relations. Cookies are used to offer you a better browsing experience and to analyze our traffic. 23) diluted earnings per. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. S. 9 million, adjusted EBITDA of $2. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. View real-time stock prices and stock quotes for a full financial overview. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. 00%. Theratechnologies, Inc. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. : Nasdaq Theratechnologies Inc. It's a different kind of fat that may require a different type of treatment. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. MONTREAL, Feb. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. com. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Denis Boucher. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 08 (+6. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. Consensus forecasts updated Jul 21. THERATECHNOLOGIES INC. Losses were -47. home message. Share your ideas and get valuable. We also use them to share usage information with our partners. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Katana shareholders will. stock news by MarketWatch. Stockhouse. By continuing to use our service, you agree to our use of cookies. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. MONTREAL, Feb. : 001-35203 Mr. . Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. Biopharmaceutical company Theratechnologies Inc. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. Theratechnologies Inc. znewcar1. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. 1. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. - Q3 2022 Consolidated Revenue Growth of 17% to $20. About Theratechnologies. View real-time stock prices and stock quotes for a full financial overview. stock news by MarketWatch. We also use them to share usage. View real-time stock prices and stock quotes for a full financial overview. TH | July 20, 2023. TH | February 28, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. : Renegotiated Lease to Generate Substantial Annual Savings. Competitors: Unknown. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. MONTREAL, Aug. We currently market prescription products for people with HIV in the United States. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. 5%. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. Stockhouse. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. The business had revenue of $27. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. GlobeNewswire. 's motion for leave to commence. MONTREAL, Sept. Stockhouse. We also use them to share. 8. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Find the latest Theratechnologies Inc. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. com uses cookies on this site. ET. T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2013-04-03 | TSX:TH) Theratechnologies Inc. Montréal, Québec, Canada . 's motion for leave to commence. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. 06 million, an increase of 14. com uses cookies on this site. - On track to meet FY2022. MONTREAL, Feb. Following the release, Knight will hold a conference call and audio webcast. 69 to $1. Thank you. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. There are 102 news items for this page. We currently market prescription products for people with HIV in the United States. By continuing to use our service, you agree to our use of cookies. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. 4. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. com uses cookies on this site. 4% from the stock's current price. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. By continuing to use our service, you agree to our use of cookies. Data presented at AMCP Nexus 2023. Saint-Laurent, Canada. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. TH1902 combines Theratechnologies’ proprietary peptide to. com uses cookies on this site.